1.	Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100856, 212082PCR4003, NCT01692483
2.	Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR017479, 212082PCR3001, NCT01217697
3.	A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: CR100797, 212082PCR3010, 2011-005243-28, NCT01517802
4.	Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100011, ABI-PRO-3002, NCT01591122
5.	A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100010, ABI-PRO-3001, NCT01695135
6.	A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Patients With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100900, 212082PCR3011, 2012-002940-26, U1111-1135-7146, NCT01715285
7.	Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000614059, CRUK-CR9304-21, EUDRACT-2007-003240-30, CR9304-21, NCT00755885
8.	A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: AT13387-04, NCT01685268
9.	Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-120, NCT01688492
10.	A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UCSF CC#125510, NCT01717898
11.	Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEP12-UC-0101/1104, NCT01780220
12.	Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016945, COU-AA-203, NCT01088529
13.	Maximum Androgen Depletion Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0070, NCT01254864
14.	S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000696565, S1014, U10CA032102, SWOG-S1014, NCT01309672
15.	IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CR017932, Protocol 212082PCR2005, NCT01314118
16.	A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR018286, 212082BCA2001, 2011-000621-80, NCT01381874
17.	Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 7639, NCI-2011-03745, NCT01503229
18.	Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 11-0709, NCI-2012-00116, NCT01543776
19.	AMG 386 and Abiraterone for Advanced Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120079, 12-C-0079, NCT01553188
20.	Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01149, 12-0109, N01CM00071, U01CA070095, UCCRC-IL057, IL057, 9012, NCT01576172
21.	A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UCSF Protocol No. 12551, NCT01637402
22.	A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: 9785-CL-0011, NCT01650194
23.	Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 90 Sponsor: Other Protocol IDs: MetAb-Pro, NCT01677897
24.	OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU12-159, NCT01681433
25.	Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 4P-12-1, NCI-2012-01485, NCT01685125